Patrick Neven, MD, Universitair Ziekenhuis Leuven, Leuven, Belgium, presents data from the EMBER-2 window-of-opportunity study, in which imlunestrant was given for about 2 weeks before surgery in women…
In this video, Virginia Kaklamani, MD, UT Health San Antonio, Texas, reviews the results of the EMBER-3 Phase 3 trial of imlunestrant, an oral SERD, in patients with…
Obi Umeh, MD, MSc, VP, Franchise Global Program Leader at Takeda, discusses interim results from a study investigating mezagitamab for the treatment of patients with IgA nephropathy. This…
In an interview conducted at the 2024 Congress of the European Hematology Association in Madrid, Spain, Lindsay Rein, MD, Duke University Medical Center, Durham, North Carolina, provided insights…
Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, discusses promising results from current clinical trials for newly diagnosed multiple myeloma. The GRIFFIN trial…
Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the…
Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, senior physician at Dana-Farber Cancer Institute, and Jerome and Nancy…
Long-term data from the KEYNOTE-010 trial showed that 35% of over 1,000 patients with non-small cell lung cancer (NSCLC) who had progressed on chemotherapy and were then treated…
